Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age

Human Psychopharmacology

Volumn 19, Issue 6, 2004, Pages 405-408

  Morishita, Shigeru ^a,b   Arita, Seizaburo ^b  

^a Kyoto Jujo Rehabilitation Hospital   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Age; Depression; Fluvoxamine; Milnacipran; Paroxetine

Indexed keywords

ANTIDEPRESSANT AGENT; FLUVOXAMINE; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL SCHOOL; OUTPATIENT; PHYSICIAN; PRIORITY JOURNAL; PSYCHIATRIC DEPARTMENT; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYCLOPROPANES; DEPRESSION; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 4444241197     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.608     Document Type: Article

References (17)

1. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
2. Hamilton M. 1986. Depression in the fifties. Gerontology 32(Suppl. 1): 14-16.
3. Hyttel J, Christensen AV, Fjalland B. 1980. Neuropharmacological properties of amitriptyline, nortriptyline and their metabolites. Acta Pharmacol Toxicol(Copenh) 47: 53-57.
4. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM. 2003. A differential response to nortriptyline and fluvoxamine in melancholic depression: the importance of age and gender. Acta Psychiatr Scand 108: 20-23.
5. Morishita S, Arita S. 2002. Induction of mania in depression by fluvoxamine. Int Med J 9: 271-273.
6. Morishita S, Arita S. 2003a. Possible predictors of response of fluvoxamine for depression. Hum Psychopharmacol Clin Exp 18: 197-200.
7. Morishita S, Arita S. 2003b. Suitable dose and duration of fluvoxamine administration to treat depression. Psychiat Clin Neurosci 57: 179-183.
8. Morishita S, Arita S. 2003c. The clinical use of milnacipran for depression. Eur Psychiatry 18: 34-35.
9. Morishita S, Arita S. 2003d. Induction of mania in depression by paroxetine. Hum Psychopharmacol Clin Exp 18: 565-568.
10. Morishita S, Arita S. 2003e. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Hum Psychopharmacol Clin Exp 18: 479-482.
11. Morishita S, Arita S. 2003f. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Eur Psychiatry 18: 418-420.
12. Mulder RT, Watkins WG, Joyce PR, Luty SE. 2003. Age may affect response to antidepressants with serotonergic and noradrenergic action. J Affect Disord 76: 143-149.
13. Nelson JCN. 1997. Safety and tolerability of the new antidepressants. J Clin Psychiatry 58(Suppl. 6): 26-31.
14. Parker G. 2002. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 106: 168-170.
15. Prien RF, Carpenter LL, Kupfer DJ. 1991. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 48: 796-800.
16. Puech A, Montgomery SA, Prost JF, et al. 1997. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108.
17. Spencer CM, Wilde MI. 1998. Milnacipran: a review of its use in depression. Drug 56: 405-427.